U.S. markets open in 4 hours 13 minutes

  • S&P Futures

    4,425.50
    -0.25 (-0.01%)
     

  • Dow Futures

    34,983.00
    -15.00 (-0.04%)
     

  • Nasdaq Futures

    15,138.25
    +13.00 (+0.09%)
     

  • Russell 2000 Futures

    2,234.20
    +1.50 (+0.07%)
     

  • Crude Oil

    67.86
    +1.38 (+2.08%)
     

  • Gold

    1,731.70
    +5.20 (+0.30%)
     

  • Silver

    23.47
    +0.20 (+0.84%)
     

  • EUR/USD

    1.1733
    -0.0007 (-0.06%)
     

  • 10-Yr Bond

    1.3170
    0.0000 (0.00%)
     

  • Vix

    16.70
    +0.55 (+3.41%)
     

  • GBP/USD

    1.3863
    +0.0012 (+0.09%)
     

  • USD/JPY

    110.4870
    +0.1820 (+0.16%)
     

  • BTC-USD

    46,016.68
    +1,835.20 (+4.15%)
     

  • CMC Crypto 200

    1,129.30
    +69.97 (+6.60%)
     

  • FTSE 100

    7,124.48
    -7.82 (-0.11%)
     

  • Nikkei 225

    27,888.15
    +68.11 (+0.24%)
     

Global Remdesivir market is expected to reach USD9913.38 million by 2026

ReportLinker
·5 min read

Remdesivir, a drug originally developed by Gilead Sciences, Inc. for the treatment of Ebola, is an antiviral medication belonging to the drug class of protease inhibitors. Remdesivir is a nucleotide analog particularly of adenosine, which shuts down the viral replication process by inhibiting the activity of an important viral enzyme RNA-dependent RNA polymerase.

New York, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Remdesivir Market, By Dosage Form, By Route of Administration, By Patient Age, By Application, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2026" - https://www.reportlinker.com/p06128263/?utm_source=GNW
The drug basically causes mutation in viral genome and blocks polymerase enzymes function, which brings about premature termination of viral replication.

The global remdesivir market is driven by the increasing prevalence of COVID-19 pandemic across different parts of the globe.Remdesivir has been found to be effective in treating novel coronavirus disease patients across different parts of the globe.

The Chinese have also been using the drug on compassionate use basis.Additionally, the drug was also used on the very first COVID-19 patient in the US, a young man in Snohomish country in Washington.

He was given the drug when his condition worsened, and signs of improvement were observed on the very next day in his condition after the drug administration.A Californian patient, who the doctors thought, will not survive, also recovered after getting remdesivir.

Promising results were also observed in Japan on 14 patients. After such cases and evidences, the US Food and Drug Administration granted approval to Remdesivir in Oct 2020 and the world is hoping that it will emerge out as a successful coronavirus treatment in coming years as well.

The global remdesivir market is segmented based on dosage form, route of administration, patient age, distribution channel, application, company, and region.Based on dosage form, the market can be categorized into frozen solution, and lyophilized solution.

The lyophilized segment is expected to hold significant market share on account of their longer shelf life. Additionally, they are cost effective, safe and an effective way to deliver medication.

Regionally, Asia Pacific is expected to witness significant growth during the forecast period in the overall remdesivir market owing to increasing number of COVID-19 patients and huge number of hospitalization cases along with increasing demand for remdesivir for the treatment of COVID-19.

Major players operating in the global remdesivir market include Gilead Sciences, Inc., Cipla Ltd., Hetero Labs Ltd., Meda Pharma SA (VIATRIS Pharmaceuticals Ltd.), Dr Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Cadila Healthcare Ltd., Jubilant Pharmova Ltd., Eva Pharma, Ferozsons Laboratories and others.

Years considered for this report:

Base Year: 2020
Estimated Year: 2021E
Forecast Period: 2022F–2026F

Objective of the Study:

• To analyze and estimate the market size of global remdesivir market in 2020.
• To estimate and forecast the market size of global remdesivir market from 2021 to 2026 and growth rate until 2026.
• To classify and forecast global remdesivir market based on dosage form, route of administration, patient age, application, distribution channel, company, and regional distribution.
• To identify dominant region or segment in the global remdesivir market.
• To identify drivers and challenges for global remdesivir market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global remdesivir market.
• To conduct pricing analysis for global remdesivir market.
• To identify and analyze the profile of leading players operating in global remdesivir market.
• To identify key sustainable strategies adopted by market players in global remdesivir market.
The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of manufacturers across the globe.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, the analyst could include the manufacturers which could not be identified due to the limitations of secondary research. The analyst examined the manufacturers, distribution channels and presence of all major players across the globe.
The analyst calculated the market size of global remdesivir market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

Key Target Audience:

• Remdesivir manufacturers, suppliers, distributors and other stakeholders
• Government bodies such as regulating authorities and policy makers
• Organizations, forums and alliances related to remdesivir
• Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global remdesivir market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
• Global Remdesivir Market, By Dosage Form:
o Lyophilized Solution
o Frozen Solution
• Global Remdesivir Market, By Route of Administration:
o Intravenous
o Inhalation
• Global Remdesivir Market, By Patient Age:
o Geriatric
o Adult
o Pediatric
• Global Remdesivir Market, By Application:
o SARS-CoV-2 (COVID-19)
o MERS-CoV
o Ebola
o SARS-CoV
• Global Remdesivir Market, By Distribution Channel:
o Hospitals
o Clinics
o Drug Stores and Pharmacies
• Global Remdesivir Market, By Region:
o North America
United States
Mexico
Canada
o Asia-Pacific
India
Japan
China
South Korea
Australia
o Europe
France
United Kingdom
Italy
Germany
Spain
o South America
Brazil
Argentina
Colombia
o Middle East & Africa
Iran
South Africa
UAE
Saudi Arabia
Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global remdesivir market.

Available Customizations:

With the given market data, we offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).
Read the full report: https://www.reportlinker.com/p06128263/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Recommended Stories

  • Why Moderna, BioNTech, and Novavax Stock Soared Today

    Moderna's shares received a boost from news that its COVID vaccine was granted provisional registration by Australia's Therapeutic Goods Administration. Moderna has agreements in place to potentially supply as many as 25 million doses of its vaccine to the Australian government by 2022. Shares of Moderna, BioNTech, and Novavax rose sharply on Monday.

  • Why Ballard Power, Plug Power, Bloom Energy, and Especially FuelCell Energy Stocks Popped Today

    Last week was an important week for the hydrogen fuel cell industry, with Ballard Power Systems (NASDAQ: BLDP), Bloom Energy (NYSE: BE), and Plug Power (NASDAQ: PLUG) reporting earnings. FuelCell Energy (NASDAQ: FCEL) was the odd man out. It reports earnings only next month -- but even FuelCell Energy had some news to report today.

  • AMC shares pop following earnings

    Shares of AMC Entertainment jump after the theater chain announced Q2 earnings. 

  • Why Shares of Vaxart Are Soaring Today

    Shares of clinical-stage vaccine developer Vaxart (NASDAQ: VXRT) are up again today, gaining 12.34% to $9.83 apiece as of 2:30 p.m. EDT. The stock is up 21% over the past five trading days due to greater capital inflows after the company released encouraging second-quarter earnings on Aug. 5. Vaxart managed to raise $36.2 million during the quarter via issuing new stock -- bringing its cash balance to $177.3 million.

  • 10 Best Lithium and Phosphate Stocks to Buy Now

    In this article, we discuss the 10 best lithium and phosphate stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Lithium and Phosphate Stocks to Buy Now. The global efforts towards decarbonization have accelerated in the past few years with the United States […]

  • Why NIO Stock Is Higher Today

    Shares of Chinese electric vehicle maker NIO (NYSE: NIO) were trading higher on Monday, after a Wall Street analyst shared an upbeat outlook for the company ahead of its second-quarter earnings report. As of 1 p.m. EDT today, NIO's American depositary shares were up about 3% from Friday's closing price. In a new note released on Monday morning, Deutsche Bank analyst Edison Yu said that he expects NIO's second-quarter results to come in above Wall Street's consensus estimate.

  • Why Axsome Therapeutics Stock Is Crashing Today

    Shares of Axsome Therapeutics (NASDAQ: AXSM), a mid-cap biotech, are down by a hefty 41.4% as of 10:08 a.m. EDT Monday morning. The drugmaker's shares are tumbling today in response to a disappointing regulatory update for AXS-05 as a potential treatment for major depressive disorder (MDD). Specifically, Axsome revealed during its 2021 second-quarter earnings release this morning that the U.S. Food and Drug Administration (FDA) had notified the company on July 30, 2021 that it has identified deficiencies within the drug's regulatory application that preclude discussion of labeling and post-marketing requirements at this time.

  • 3 Big Takeaways From Workhorse Group's Earnings Report

    Workhorse's weary investors might finally have something to cheer -- and it's not the U.S. Postal Service.

  • Why Fastly Stock Is Up Sharply on Monday

    Shares of edge computing specialist Fastly (NYSE: FSLY) are jumping on Monday. As of 11:25 a.m. EDT, the stock is up 5.4%. Two factors likely helping the stock are a bullish day for growth stocks overall and further rebounding from the stock's recent post-earnings slide.

  • If the S&P 500 breaks above this key level, it could set off an ‘epic emotional squeeze’ not unlike 1999, strategists warn

    Anear-term top for the S&P 500 could be coming, say strategists at BTIG. And meme stocks could be the trigger.

  • Warren Buffett Stocks: What's Inside Berkshire Hathaway's Portfolio?

    You must keep up on Warren Buffett stocks: The Berkshire Hathaway chief sticks to a winning investing formula, but he does not sit still.

  • Why Pinterest Stock Plunged 25% in July

    Pinterest (NYSE: PINS) stock plummeted 25.4% in July, according to data from S&P Global Market Intelligence. The catalyst was the image-sharing platform's release of its second-quarter report, which disappointed many investors. Despite July's big pullback, shares of Pinterest (which went public in April 2019) are up 68.2% over the one-year period through Aug. 9, compared with the broader market's 34.3% return over this period.

  • Is GE Stock A Buy After Reverse Stock Split And Q2 Earnings Beat?

    GE's turnaround is gaining traction as key businesses improve while the industrial giant continues to shrink its debt load.

  • Here's Why Coinbase Global, Canaan, and Ebang International Were Up Big Today

    Rising prices for leading cryptocurrencies, including Bitcoin and Ethereum's Ether, are prompting big gains for crypto-related stocks in today's trading. Coinbase Global (NASDAQ: COIN), Canaan (NASDAQ: CAN), and Ebang International Holdings (NASDAQ: EBON) are among the players in the space posting significant gains in the session. Ether's token price has risen 30% over the last month, while Bitcoin's price per token has climbed roughly 29% across the stretch.

  • Why Nokia Rallied More Than 14% in July

    The wireless networking solutions company is slowly but surely working its way back to its once-iconic form.

  • Earnings engine continues to power on, but peak growth likely behind us: strategist

    John Hancock Investment Management co-chief investment strategist Emily Roland discusses earnings season and what types of companies investors should seek as a safety trade amid rising volatility.

  • Why Editas Medicine Beat the Market on Monday

    Editas Medicine (NASDAQ: EDIT) got a spoonful of good medicine on Monday that gave its shares a healthy lift; ultimately, the stock closed the day more than 4.4% higher. Lee's new bullishness on the company, which utilizes gene-editing technology to develop medications, is due to several positive factors. Finally, in his research note, Lee touted the company's "scarcity value as a relatively unencumbered CRISPR-Cas platform company making [it] attractive as a potential partner or a target."

  • Is Upstart Holdings (UPST) A Smart Long-Term Buy?

    Vulcan Value Partners, an investment management firm, published its “Large Cap, Small Cap, Focus Composite, Focus Plus Composite, and All Cap Composite” second quarter 2021 investor letter – a copy of which can be downloaded here. Vulcan’s Large Cap Composite Fund delivered a 12.4% net return for the second quarter of 2021, 9.9% for the […]

  • Pfizer Expects $33.5 Billion In Full-Year Covid Vaccine Sales — Is PFE Stock A Buy?

    Is Pfizer stock a buy as the company expects $33.5 billion in full-year sales of its Covid vaccine? Is PFE stock a buy now?

  • ARK Invest Stocks To Buy And Watch: 6 Stocks That Cathie Wood's ARK ETFs Own; Tesla Races Higher On Upgrade

    Cathie Wood's ARK Invest ETFs are some of the hottest ETFs after 2020's huge gains. Five ARK Invest stocks to buy and watch include Coinbase and Tesla.